GlassScriptPhysician profile
Jennilyn Wetzel
NPI 1104920792
$2,482.13
in general payments reported to CMS, 2019-2025
24 companies · $66.54 in 2025
The $66.54 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $719 · 2020: $391 · 2021: $684 · 2022: $371 · 2023: $125 · 2024: $127 · 2025: $66.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $317.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $658.80 | 2019-2024 | Repatha, Otezla |
| Lilly USA, LLC | $358.97 | 2019-2022 | |
| Abbott Laboratories | $220.48 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.79 | 2020-2023 | Spiriva Respimat |
| Abbvie INC. | $135.18 | 2021-2023 | Vraylar |
| Glaxosmithkline, LLC. | $122.64 | 2019-2023 | Arexvy |
| Novartis Pharmaceuticals Corporation | $97.67 | 2019 | |
| Novo Nordisk INC | $95.83 | 2021-2023 | Rybelsus, Ozempic, Wegovy |
| Amarin Pharma, INC. | $68.13 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $65.42 | 2022 | |
| Pfizer INC. | $64.24 | 2021-2022 | |
| Genentech USA, INC. | $61.99 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.89 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $46.84 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.48 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $31.47 | 2020-2021 | |
| Qol Medical, LLC | $28.16 | 2021 | |
| Alkermes, INC. | $23.08 | 2021 | |
| Sanofi-Aventis U.S. LLC | $20.70 | 2021 | |
| Eisai INC. | $18.73 | 2021 | |
| Ibsa Pharma INC. | $16.37 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $15.80 | 2021 | |
| Bardy Diagnostics, INC. | $15.14 | 2022 | |
| Seqirus USA INC | $13.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennilyn Wetzel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.